C4 Therapeutics (CCCC) Gains from Investment Securities (2020)
C4 Therapeutics' (CCCC) quarterly Gains from Investment Securities came in at $2.5 million in Q4 2020, down 19.29% quarter-over-quarter from $3.1 million in Q3 2020.
C4 Therapeutics (CCCC) Gains from Investment Securities (2020) Analysis & Trends
C4 Therapeutics' Gains from Investment Securities history runs 1 years deep, the most recent figure standing at $2.5 million for Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,222.41 Bn | 67,222.13 Bn | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - |
| 4 | BeOne Medicines | 471.12 Bn | 466.33 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.84 Bn | 114.59 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.89 Bn | 61.14 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - |
| 8 | Argenx Se | 55.83 Bn | 50.64 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.34 Bn | 34.34 Bn | 959.66 Mn |
| 10 | C4 Therapeutics | 463.95 Mn | 228.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 2.54 Mn |
| Dec 31, 2020 | 2.54 Mn |
| Sep 30, 2020 | 3.14 Mn |
| Sep 30, 2020 | 3.14 Mn |